Amydis, Inc., founded in 2013, is a privately-held company discovering novel small molecule drugs to allow direct visualization of CNS molecular pathology through the retina to detect, monitor, and screen diseases that involve the presence of amyloid proteins. Our mission is to develop a simple, non-invasive eye test that is faster, more accessible, and more affordable than current tests. Amydis has a platform of novel compounds that fluoresce when bound to amyloid-related proteins, thus enabling visual diagnosis of such diseases. Amydis pharmacologic compounds will enable eye care specialists the ability to refer patients at risk early to neurologists, addressing a current unmet need and gap in our healthcare system where patients see a neurologist when the disease is advanced. Neurologist will have access to the first affordable and accessible tool to quantifiably monitor disease progression.